Literature DB >> 31471287

Fedratinib Becomes New Option in Myelofibrosis.

.   

Abstract

The FDA recently approved fedratinib for myelofibrosis, making it just the second drug approved for the disease, as well as the second approved JAK inhibitor. The approval was based on the phase III JAKARTA trial, in which the drug significantly reduced symptoms compared with a placebo. However, the drug comes with a Boxed Warning for encephalopathy. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID： 31471287     DOI： 10.1158/2159-8290.CD-NB2019-102

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  7 in total

1.  ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.

Authors:  Stephen T Oh; Moshe Talpaz; Aaron T Gerds; Vikas Gupta; Srdan Verstovsek; Ruben Mesa; Carole B Miller; Candido E Rivera; Angela G Fleischman; Swati Goel; Mark L Heaney; Casey O'Connell; Murat O Arcasoy; Yafeng Zhang; Jun Kawashima; Tomas Ganz; Mark Kowalski; Carrie Baker Brachmann
Journal:  Blood Adv       Date:  2020-09-22

2.  Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.

Authors:  Ryan R Davis; Baoli Li; Sang Y Yun; Alice Chan; Pradeep Nareddy; Steven Gunawan; Muhammad Ayaz; Harshani R Lawrence; Gary W Reuther; Nicholas J Lawrence; Ernst Schönbrunn
Journal:  J Med Chem       Date:  2021-02-11       Impact factor: 7.446

3.  Generation of a chemical genetic model for JAK3.

Authors:  Judit Remenyi; Rangeetha Jayaprakash Naik; Jinhua Wang; Momchil Razsolkov; Alyssa Verano; Quan Cai; Li Tan; Rachel Toth; Samantha Raggett; Carla Baillie; Ryan Traynor; C James Hastie; Nathanael S Gray; J Simon C Arthur
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

Review 4.  MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.

Authors:  Julian Grabek; Jasmin Straube; Megan Bywater; Steven W Lane
Journal:  Cells       Date:  2020-08-14       Impact factor: 6.600

5.  CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of JAK2 V617F Somatic Mutation in Myeloproliferative Neoplasms.

Authors:  Miaomiao Chen; Chunhua Zhang; Zhiqing Hu; Zhuo Li; Menglin Li; Lingqian Wu; Miaojin Zhou; Desheng Liang
Journal:  Biosensors (Basel)       Date:  2021-07-24

6.  TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers.

Authors:  Angelina T Regua; Noah R Aguayo; Sara Abu Jalboush; Daniel L Doheny; Sara G Manore; Dongqin Zhu; Grace L Wong; Austin Arrigo; Calvin J Wagner; Yang Yu; Alexandra Thomas; Michael D Chan; Jimmy Ruiz; Guangxu Jin; Roy Strowd; Peiqing Sun; Jiayuh Lin; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

7.  Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice.

Authors:  Yang Tang; Wenli Liu; Wei Wang; Trevor Fidler; Britany Woods; Ross L Levine; Alan R Tall; Nan Wang
Journal:  Cardiovasc Drugs Ther       Date:  2020-04       Impact factor: 3.727
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.